Meagan Miller

Dr. Meagan Miller


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2021 in BMJ
Verified
Journal Article
Closed access
PDF file
MMMeagan Miller
Meagan Miller
NHNasser Hanna
Nasser Hanna
Lung cancer remains a leading cause of cancer related mortality worldwide. Despite numerous advances in treatments over the past decade, non-small cell lung cancer (NSCLC) remains an incurable disease for most patients. The optimal treatment for all patients with locally advanced, but surgically resectable, NSCLC contains at least chemoradiation. Trimodality treatment with surgical resection has been a subject of debate for decades. For patients with unresectable or inoperable locally advanced disease, the incorporation of immunotherapy consolidation after chemoradiation has defined a new standard of care. For decades, the standard of care treatment for advanced stage NSCLC included only cytotoxic chemotherapy. However, with the introduction of targeted therapies and immunotherapy, the landscape of treatment has rapidly evolved. This review discusses the integration of these innovative therapies in the management of patients with newly diagnosed NSCLC.

23 June 2023 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
MMMeagan Miller
Meagan Miller
MRMahvish Q. Rahim
Mahvish Q. Rahim
SCScott L. Coven
Scott L. Coven
SJSeethal A. Jacob
Seethal A. Jacob
GZGregory D. Zimet
Gregory D. Zimet
MOMary A. Ott
Mary A. Ott
Rates of Human papilloma virus (HPV) vaccination among pediatric survivors of cancer and patients with sickle cell disease are lower than the national average. While recent attention has focused on patient HPV vaccine hesitancy and refusal, less is known about provider-level and system-level barriers to vaccinations in pediatric hematology/oncology (PHO) populations. Applying thematic analysis to qualitative interviews with 20 pediatric hematology/oncology physicians and nurse practitioners, we examine their views regarding HPV vaccination, with a focus on access and barriers to providing HPV vaccination in PHO practices. Results demonstrated that despite 90% of interviewees supporting HPV vaccination in their population, the number of pediatric hematology/oncology providers who reported that they counsel about HPV or provide HPV vaccination was 45%, even in stem cell and sickle cell clinics, where other childhood vaccines are commonly provided. Clinicians identified provider-level, clinic-level, and system-level barriers to giving the HPV vaccination, including but not limited to time/flow constraints, lack of resources, and continued education regarding the HPV vaccine. These barriers impede the ability for pediatric hematology/oncology providers to counsel and provide HPV vaccination to this specialized population.

28 March 2022 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
MMMeagan Miller
Meagan Miller
MRMahvish Q. Rahim
Mahvish Q. Rahim
SCScott L. Coven
Scott L. Coven
SJSeethal A. Jacob
Seethal A. Jacob
GZGregory D. Zimet
Gregory D. Zimet
MOMary A. Ott
Mary A. Ott
As of 05/28/2021, SARS-CoV-2 (COVID-19) had caused 3.9 million infections in the United States (US) pediatric population since its discovery in December of 2019. The development and expansion of vaccination has markedly changed the shape of the epidemic. In this qualitative study, we report on pediatric hematology/oncology provider views on the COVID-19 vaccine prior to approval in the adolescent population <16 years of age. Results from interviews with 20 providers across the state of Indiana showed that most were supportive of the COVID-19 vaccine for healthy adults. However, the majority also expressed a need to see more data on the safety and effectiveness of COVID-19 vaccinations in pediatric hematology/oncology populations. While they recognized the public health importance of vaccination, their duty to protect their patients led to a need for more specific safety and efficacy data.

10 December 2020 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MMMeagan Miller
Meagan Miller

1 January 2025 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SCSuparna C. Clasen
Suparna C. Clasen
MMMeagan Miller
Meagan Miller
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology , to patients seen in their own clinical practice.